JP2019534304A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534304A5
JP2019534304A5 JP2019524273A JP2019524273A JP2019534304A5 JP 2019534304 A5 JP2019534304 A5 JP 2019534304A5 JP 2019524273 A JP2019524273 A JP 2019524273A JP 2019524273 A JP2019524273 A JP 2019524273A JP 2019534304 A5 JP2019534304 A5 JP 2019534304A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
pharmaceutically acceptable
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019524273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/078701 external-priority patent/WO2018087202A1/en
Publication of JP2019534304A publication Critical patent/JP2019534304A/ja
Publication of JP2019534304A5 publication Critical patent/JP2019534304A5/ja
Withdrawn legal-status Critical Current

Links

JP2019524273A 2016-11-10 2017-11-09 炎症性疾患の治療のための化合物及びその医薬組成物 Withdrawn JP2019534304A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB201618959 2016-11-10
GB201618962 2016-11-10
GB201618963 2016-11-10
GB1618959.9 2016-11-10
GB1618962.3 2016-11-10
GB1618963.1 2016-11-10
GB1618961.5 2016-11-10
GB1618960.7 2016-11-10
GB1618964.9 2016-11-10
GB201618961 2016-11-10
GB201618964 2016-11-10
GB201618960 2016-11-10
PCT/EP2017/078701 WO2018087202A1 (en) 2016-11-10 2017-11-09 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2019534304A JP2019534304A (ja) 2019-11-28
JP2019534304A5 true JP2019534304A5 (cg-RX-API-DMAC7.html) 2020-12-17

Family

ID=60388032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524273A Withdrawn JP2019534304A (ja) 2016-11-10 2017-11-09 炎症性疾患の治療のための化合物及びその医薬組成物

Country Status (8)

Country Link
US (1) US20190314382A1 (cg-RX-API-DMAC7.html)
EP (1) EP3538103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019534304A (cg-RX-API-DMAC7.html)
AU (1) AU2017358703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043396A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019117562A (cg-RX-API-DMAC7.html)
TW (1) TW201821080A (cg-RX-API-DMAC7.html)
WO (1) WO2018087202A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019132654A1 (en) * 2017-12-27 2019-07-04 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020009566A1 (en) * 2018-07-04 2020-01-09 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN115282168B (zh) * 2022-08-30 2024-05-31 马应龙大健康有限公司 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用
CN119157881A (zh) * 2024-09-25 2024-12-20 Jje有限公司 Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111956A1 (en) 2003-07-03 2007-05-17 Japan Science And Technology Agency Remedy for sarcoidosis and method of treating the same
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
DK2830662T3 (da) * 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
KR20170134750A (ko) 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
AU2016259023A1 (en) * 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth

Similar Documents

Publication Publication Date Title
JP5819328B2 (ja) ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
JP2020526483A5 (cg-RX-API-DMAC7.html)
JP7852200B2 (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
TWI907406B (zh) 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
EP2838530B1 (en) Methods for treating parkinson's disease
CN101511366A (zh) 在心肌显像方法期间用于增加患者耐受性的方法和组合物
RU2019117562A (ru) Соединения и их фармацевтические композиции для лечения воспалительных заболеваний
AU2020278236A1 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
JP2014520856A (ja) 併用als療法
EP3154517A1 (en) Stabilized oxymetazoline formulations and their uses
JP2017519034A (ja) 手足症候群及び前記症候群に随伴する症候を治療する方法
CN101677972A (zh) 一种用于治疗神经变性疾病的奈拉美生的新组合物
UA112406C2 (uk) Фармацевтична комбінація, яка містить тестостерон та інгібітор фде5, для лікування жіночої сексуальної дисфункції
IL289841B (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
US20230147835A1 (en) Methods of treating systemic sclerosis
KR102728341B1 (ko) 원형탈모증의 치료
US20170333428A1 (en) Methods for Treating HCV
EP3265095B1 (en) Use of n-desmethylclobazam in the treatment of chronic pain disorders and related methods
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
CN107249596A (zh) 多发性骨髓瘤的帕比司他剂量
EP4271477A1 (en) <sup2/>? <sub2/>?4?dual inhibition of sars-cov-2 virus of leukotriene ltdreceptor antagonist montelukast
TW201705957A (zh) 額葉功能障礙之治療劑
HK40087403A (en) Methods of treating relapsing multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
Van Wart et al. PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF TOLVAPTAN ON FLUID AND ELECTROLYTE BALANCE IN PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
HK1177139A (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide